Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions.

Seale AC, Baker CJ, Berkley JA, Madhi SA, Ordi J, Saha SK, Schrag SJ, Sobanjo-Ter Meulen A, Vekemans J.

Vaccine. 2019 Aug 14;37(35):4877-4885. doi: 10.1016/j.vaccine.2019.07.012. Epub 2019 Jul 11. Review.

2.

New hope for tuberculosis vaccines.

Olesen OF, Abdullah F, Coppens R, Gardner PJ, Ginsberg AM, Hanekom WA, Laang H, Lewinsohn DM, Loots G, Schmidt A, Vekemans J, Voss GH.

Lancet Infect Dis. 2019 Jul;19(7):687-688. doi: 10.1016/S1473-3099(19)30280-4. No abstract available.

PMID:
31250810
3.

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.

Vekemans J, Crofts J, Baker CJ, Goldblatt D, Heath PT, Madhi SA, Le Doare K, Andrews N, Pollard AJ, Saha SK, Schrag SJ, Smith PG, Kaslow DC.

Vaccine. 2019 May 27;37(24):3190-3198. doi: 10.1016/j.vaccine.2019.04.039. Epub 2019 Apr 25. Review.

4.

Tuberculosis vaccines: Rising opportunities.

Vekemans J, O'Brien KL, Farrar J.

PLoS Med. 2019 Apr 23;16(4):e1002791. doi: 10.1371/journal.pmed.1002791. eCollection 2019 Apr.

5.

Research and development of new tuberculosis vaccines: a review.

Schrager LK, Harris RC, Vekemans J.

Version 2. F1000Res. 2018 Nov 1 [revised 2019 Jan 1];7:1732. doi: 10.12688/f1000research.16521.2. eCollection 2018. Review.

6.

The way forward for tuberculosis vaccines.

White RG, Hanekom WA, Vekemans J, Harris RC.

Lancet Respir Med. 2019 Mar;7(3):204-206. doi: 10.1016/S2213-2600(19)30040-2. No abstract available. Erratum in: Lancet Respir Med. 2019 Apr;7(4):e15.

PMID:
30823973
7.

A new tuberculosis vaccine: breakthrough, challenges, and a call for collaboration.

Vekemans J, Gebreselassie N, Zignol M, Friede M, Kasaeva T, Swaminathan S.

Lancet Infect Dis. 2019 Feb;19(2):123-125. doi: 10.1016/S1473-3099(19)30003-9. Epub 2019 Jan 30. No abstract available.

PMID:
30712831
8.

Serocorrelates of protection against infant group B streptococcus disease.

Le Doare K, Kampmann B, Vekemans J, Heath PT, Goldblatt D, Nahm MH, Baker C, Edwards MS, Kwatra G, Andrews N, Madhi SA, Ter Meulen AS, Anderson AS, Corsaro B, Fischer P, Gorringe A.

Lancet Infect Dis. 2019 May;19(5):e162-e171. doi: 10.1016/S1473-3099(18)30659-5. Epub 2019 Jan 22. Review.

PMID:
30683467
9.

The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.

Vekemans J, Gouvea-Reis F, Kim JH, Excler JL, Smeesters PR, O'Brien KL, Van Beneden CA, Steer AC, Carapetis JR, Kaslow DC.

Clin Infect Dis. 2019 Aug 16;69(5):877-883. doi: 10.1093/cid/ciy1143.

10.

Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, Payne R, Powlson J, Bliss C, Venkatraman N, Poulton ID, de Graaf H, Gbesemete D, Grobbelaar A, Davies H, Roberts R, Angus B, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee C, Ockenhouse C, Sinden RE, Gerry SC, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Lewis DJM, Cooke GS, Faust SN, Gilbert S, Hill AVS.

NPJ Vaccines. 2018 Oct 9;3:49. doi: 10.1038/s41541-018-0084-2. eCollection 2018.

11.

WHO preferred product characteristics for new vaccines against tuberculosis.

Schrager LK, Chandrasekaran P, Fritzell BH, Hatherill M, Lambert PH, McShane H, Tornieporth N, Vekemans J.

Lancet Infect Dis. 2018 Aug;18(8):828-829. doi: 10.1016/S1473-3099(18)30421-3. No abstract available.

PMID:
30064668
12.

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates.

Mazur NI, Higgins D, Nunes MC, Melero JA, Langedijk AC, Horsley N, Buchholz UJ, Openshaw PJ, McLellan JS, Englund JA, Mejias A, Karron RA, Simões EA, Knezevic I, Ramilo O, Piedra PA, Chu HY, Falsey AR, Nair H, Kragten-Tabatabaie L, Greenough A, Baraldi E, Papadopoulos NG, Vekemans J, Polack FP, Powell M, Satav A, Walsh EE, Stein RT, Graham BS, Bont LJ; Respiratory Syncytial Virus Network (ReSViNET) Foundation.

Lancet Infect Dis. 2018 Oct;18(10):e295-e311. doi: 10.1016/S1473-3099(18)30292-5. Epub 2018 Jun 18. Review. Erratum in: Lancet Infect Dis. 2018 Jul 25;:.

13.

Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.

Valéa I, Adjei S, Usuf E, Traore O, Ansong D, Tinto H, Owusu Boateng H, Leach A, Mwinessobaonfou Some A, Buabeng P, Vekemans J, Nana LA, Kotey A, Vandoolaeghe P, Ouedraogo F, Sambian D, Lievens M, Tahita MC, Rettig T, Jongert E, Lompo P, Idriss A, Borys D, Ouedraogo S, Prempeh F, Habib MA, Schuerman L, Sorgho H, Agbenyega T.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1489-1500. doi: 10.1080/21645515.2018.1442996. Epub 2018 Apr 13.

14.

WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.

Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC.

Vaccine. 2018 Jun 7;36(24):3397-3405. doi: 10.1016/j.vaccine.2018.02.068. Epub 2018 Feb 26.

PMID:
29496349
15.

RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.

Nielsen CM, Vekemans J, Lievens M, Kester KE, Regules JA, Ockenhouse CF.

Vaccine. 2018 Mar 14;36(12):1637-1642. doi: 10.1016/j.vaccine.2018.01.069. Epub 2018 Feb 10.

16.

Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.

Witte D, Cunliffe NA, Turner AM, Ngulube E, Ofori-Anyinam O, Vekemans J, Chimpeni P, Lievens M, Wilson TP, Njiram'madzi J, Mendoza YG, Leach A.

Pediatr Infect Dis J. 2018 May;37(5):483-491. doi: 10.1097/INF.0000000000001937.

PMID:
29432383
17.

Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics.

Vekemans J, Moorthy V, Friede M, Alderson MR, Sobanjo-Ter Meulen A, Baker CJ, Heath PT, Madhi SA, Mehring-Le Doare K, Saha SK, Schrag S, Kaslow DC.

Vaccine. 2018 Feb 2. pii: S0264-410X(17)31359-2. doi: 10.1016/j.vaccine.2017.09.087. [Epub ahead of print] Review.

18.

Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.

Vekemans J, Moorthy V, Giersing B, Friede M, Hombach J, Arora N, Modjarrad K, Smith PG, Karron R, Graham B, Kaslow D.

Vaccine. 2018 Jan 25. pii: S0264-410X(17)31364-6. doi: 10.1016/j.vaccine.2017.09.092. [Epub ahead of print] Review.

PMID:
29395536
19.

Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.

Seale AC, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, Madrid L, Blencowe H, Cousens S, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag SJ, Sobanjo-Ter Meulen A, Vekemans J, Lawn JE.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S200-S219. doi: 10.1093/cid/cix664.

20.

Neurodevelopmental Impairment in Children After Group B Streptococcal Disease Worldwide: Systematic Review and Meta-analyses.

Kohli-Lynch M, Russell NJ, Seale AC, Dangor Z, Tann CJ, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, O'Sullivan C, Nakwa F, Ben Hamouda H, Soua H, Giorgakoudi K, Ladhani S, Lamagni T, Rattue H, Trotter C, Lawn JE.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S190-S199. doi: 10.1093/cid/cix663. Review.

21.

Neonatal Encephalopathy With Group B Streptococcal Disease Worldwide: Systematic Review, Investigator Group Datasets, and Meta-analysis.

Tann CJ, Martinello KA, Sadoo S, Lawn JE, Seale AC, Vega-Poblete M, Russell NJ, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Heath PT; GBS Neonatal Encephalopathy Investigator Group.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S173-S189. doi: 10.1093/cid/cix662. Review.

22.

Preterm Birth Associated With Group B Streptococcus Maternal Colonization Worldwide: Systematic Review and Meta-analyses.

Bianchi-Jassir F, Seale AC, Kohli-Lynch M, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Rubens CE.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S133-S142. doi: 10.1093/cid/cix661. Review.

23.

Maternal Disease With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses.

Hall J, Adams NH, Bartlett L, Seale AC, Lamagni T, Bianchi-Jassir F, Lawn JE, Baker CJ, Cutland C, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Gravett MG.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S112-S124. doi: 10.1093/cid/cix660. Review.

24.

Maternal Colonization With Group B Streptococcus and Serotype Distribution Worldwide: Systematic Review and Meta-analyses.

Russell NJ, Seale AC, O'Driscoll M, O'Sullivan C, Bianchi-Jassir F, Gonzalez-Guarin J, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Le Doare K, Madhi SA, Rubens CE, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Saha SK, Ip M; GBS Maternal Colonization Investigator Group.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S100-S111. doi: 10.1093/cid/cix658. Review.

25.

Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses.

Madrid L, Seale AC, Kohli-Lynch M, Edmond KM, Lawn JE, Heath PT, Madhi SA, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Le Doare K, Rubens CE, Saha SK, Sobanjo-Ter Meulen A, Vekemans J, Schrag S; Infant GBS Disease Investigator Group.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S160-S172. doi: 10.1093/cid/cix656. Review.

26.

Risk of Early-Onset Neonatal Group B Streptococcal Disease With Maternal Colonization Worldwide: Systematic Review and Meta-analyses.

Russell NJ, Seale AC, O'Sullivan C, Le Doare K, Heath PT, Lawn JE, Bartlett L, Cutland C, Gravett M, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Baker CJ.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S152-S159. doi: 10.1093/cid/cix655. Review.

27.

Intrapartum Antibiotic Chemoprophylaxis Policies for the Prevention of Group B Streptococcal Disease Worldwide: Systematic Review.

Le Doare K, O'Driscoll M, Turner K, Seedat F, Russell NJ, Seale AC, Heath PT, Lawn JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Ip M, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Kampmann B; GBS Intrapartum Antibiotic Investigator Group.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S143-S151. doi: 10.1093/cid/cix654. Review.

28.

Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children: Why, What, and How to Undertake Estimates?

Lawn JE, Bianchi-Jassir F, Russell NJ, Kohli-Lynch M, Tann CJ, Hall J, Madrid L, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Ip M, Le Doare K, Madhi SA, Rubens CE, Saha SK, Schrag S, Sobanjo-Ter Meulen A, Vekemans J, Seale AC.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S89-S99. doi: 10.1093/cid/cix653.

29.

Stillbirth With Group B Streptococcus Disease Worldwide: Systematic Review and Meta-analyses.

Seale AC, Blencowe H, Bianchi-Jassir F, Embleton N, Bassat Q, Ordi J, Menéndez C, Cutland C, Briner C, Berkley JA, Lawn JE, Baker CJ, Bartlett L, Gravett MG, Heath PT, Ip M, Le Doare K, Rubens CE, Saha SK, Schrag S, Meulen AS, Vekemans J, Madhi SA.

Clin Infect Dis. 2017 Nov 6;65(suppl_2):S125-S132. doi: 10.1093/cid/cix585. Review.

30.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbé GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ.

JCI Insight. 2017 Nov 2;2(21). pii: 96381. doi: 10.1172/jci.insight.96381.

31.

Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial.

van den Berg RA, Coccia M, Ballou WR, Kester KE, Ockenhouse CF, Vekemans J, Jongert E, Didierlaurent AM, van der Most RG.

Front Immunol. 2017 May 23;8:557. doi: 10.3389/fimmu.2017.00557. eCollection 2017.

32.

Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.

Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS.

Vaccine. 2017 Mar 14. pii: S0264-410X(17)30293-1. doi: 10.1016/j.vaccine.2017.02.068. [Epub ahead of print]

33.

Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.

Laurens MB, Kouriba B, Bergmann-Leitner E, Angov E, Coulibaly D, Diarra I, Daou M, Niangaly A, Blackwelder WC, Wu Y, Cohen J, Ballou WR, Vekemans J, Lanar DE, Dutta S, Diggs C, Soisson L, Heppner DG, Doumbo OK, Plowe CV, Thera MA.

PLoS One. 2017 Mar 10;12(3):e0173294. doi: 10.1371/journal.pone.0173294. eCollection 2017.

34.

Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.

Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V; WHO Product Development for Vaccines Advisory Committee.

Vaccine. 2017 Mar 2. pii: S0264-410X(16)31205-1. doi: 10.1016/j.vaccine.2016.10.090. [Epub ahead of print]

PMID:
28262332
35.

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.

Kobayashi M, Schrag SJ, Alderson MR, Madhi SA, Baker CJ, Sobanjo-Ter Meulen A, Kaslow DC, Smith PG, Moorthy VS, Vekemans J.

Vaccine. 2016 Dec 22. pii: S0264-410X(16)31236-1. doi: 10.1016/j.vaccine.2016.12.029. [Epub ahead of print]

36.

Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Kobayashi M, Vekemans J, Baker CJ, Ratner AJ, Le Doare K, Schrag SJ.

F1000Res. 2016 Sep 22;5:2355. eCollection 2016. Review.

37.

Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.

Otieno L, Oneko M, Otieno W, Abuodha J, Owino E, Odero C, Mendoza YG, Andagalu B, Awino N, Ivinson K, Heerwegh D, Otsyula N, Oziemkowska M, Usuf EA, Otieno A, Otieno K, Leboulleux D, Leach A, Oyieko J, Slutsker L, Lievens M, Cowden J, Lapierre D, Kariuki S, Ogutu B, Vekemans J, Hamel MJ.

Lancet Infect Dis. 2016 Oct;16(10):1134-1144. doi: 10.1016/S1473-3099(16)30161-X. Epub 2016 Jul 7.

PMID:
27394191
38.

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.

Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM, Poulton ID, de Graaf H, Sukhtankar P, Roberts R, Ivinson K, Weltzin R, Rajkumar BY, Wille-Reece U, Lee CK, Ockenhouse CF, Sinden RE, Gerry S, Lawrie AM, Vekemans J, Morelle D, Lievens M, Ballou RW, Cooke GS, Faust SN, Gilbert S, Hill AV.

J Infect Dis. 2016 Sep 1;214(5):772-81. doi: 10.1093/infdis/jiw244. Epub 2016 Jun 15.

39.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J.

J Infect Dis. 2016 Sep 1;214(5):762-71. doi: 10.1093/infdis/jiw237. Epub 2016 Jun 13.

PMID:
27296848
40.

Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate.

Graves SF, Kouriba B, Diarra I, Daou M, Niangaly A, Coulibaly D, Keita Y, Laurens MB, Berry AA, Vekemans J, Ripley Ballou W, Lanar DE, Dutta S, Gray Heppner D, Soisson L, Diggs CL, Thera MA, Doumbo OK, Plowe CV, Sztein MB, Lyke KE.

Vaccine. 2016 May 17;34(23):2546-55. doi: 10.1016/j.vaccine.2016.04.019. Epub 2016 Apr 15.

PMID:
27087149
41.

Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Bennett JW, Yadava A, Tosh D, Sattabongkot J, Komisar J, Ware LA, McCarthy WF, Cowden JJ, Regules J, Spring MD, Paolino K, Hartzell JD, Cummings JF, Richie TL, Lumsden J, Kamau E, Murphy J, Lee C, Parekh F, Birkett A, Cohen J, Ballou WR, Polhemus ME, Vanloubbeeck YF, Vekemans J, Ockenhouse CF.

PLoS Negl Trop Dis. 2016 Feb 26;10(2):e0004423. doi: 10.1371/journal.pntd.0004423. eCollection 2016 Feb.

42.

Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.

Payne RO, Milne KH, Elias SC, Edwards NJ, Douglas AD, Brown RE, Silk SE, Biswas S, Miura K, Roberts R, Rampling TW, Venkatraman N, Hodgson SH, Labbé GM, Halstead FD, Poulton ID, Nugent FL, de Graaf H, Sukhtankar P, Williams NC, Ockenhouse CF, Kathcart AK, Qabar AN, Waters NC, Soisson LA, Birkett AJ, Cooke GS, Faust SN, Woods C, Ivinson K, McCarthy JS, Diggs CL, Vekemans J, Long CA, Hill AV, Lawrie AM, Dutta S, Draper SJ.

J Infect Dis. 2016 Jun 1;213(11):1743-51. doi: 10.1093/infdis/jiw039. Epub 2016 Feb 4. Erratum in: J Infect Dis. 2016 Sep 15;214(6):978.

43.

The March Toward Malaria Vaccines.

Hoffman SL, Vekemans J, Richie TL, Duffy PE.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S319-33. doi: 10.1016/j.amepre.2015.09.011. Review.

44.

The march toward malaria vaccines.

Hoffman SL, Vekemans J, Richie TL, Duffy PE.

Vaccine. 2015 Nov 27;33 Suppl 4:D13-23. doi: 10.1016/j.vaccine.2015.07.091. Epub 2015 Aug 29. Review.

45.

Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults.

Ockenhouse CF, Regules J, Tosh D, Cowden J, Kathcart A, Cummings J, Paolino K, Moon J, Komisar J, Kamau E, Oliver T, Chhoeu A, Murphy J, Lyke K, Laurens M, Birkett A, Lee C, Weltzin R, Wille-Reece U, Sedegah M, Hendriks J, Versteege I, Pau MG, Sadoff J, Vanloubbeeck Y, Lievens M, Heerwegh D, Moris P, Guerra Mendoza Y, Jongert E, Cohen J, Voss G, Ballou WR, Vekemans J.

PLoS One. 2015 Jul 6;10(7):e0131571. doi: 10.1371/journal.pone.0131571. eCollection 2015.

46.

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.

Ajua A, Lell B, Agnandji ST, Asante KP, Owusu-Agyei S, Mwangoka G, Mpina M, Salim N, Tanner M, Abdulla S, Vekemans J, Jongert E, Lievens M, Cambron P, Ockenhouse CF, Kremsner PG, Mordmüller B.

Malar J. 2015 Feb 13;14:72. doi: 10.1186/s12936-015-0605-7.

47.

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children.

Olotu A, Clement F, Jongert E, Vekemans J, Njuguna P, Ndungu FM, Marsh K, Leroux-Roels G, Bejon P.

PLoS One. 2014 Dec 15;9(12):e115126. doi: 10.1371/journal.pone.0115126. eCollection 2014.

48.

Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.

Miura K, Jongert E, Deng B, Zhou L, Lusingu JP, Drakeley CJ, Fay MP, Long CA, Vekemans J.

Malar J. 2014 Jul 9;13:263. doi: 10.1186/1475-2875-13-263.

49.

Triple helix formation in amphiphilic discotics: demystifying solvent effects in supramolecular self-assembly.

Gillissen MA, Koenigs MM, Spiering JJ, Vekemans JA, Palmans AR, Voets IK, Meijer EW.

J Am Chem Soc. 2014 Jan 8;136(1):336-43. doi: 10.1021/ja4104183. Epub 2013 Dec 19.

PMID:
24313787
50.

Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.

Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Dube T, Soisson L, Diggs CL, House B, Bennett JW, Lanar DE, Dutta S, Heppner DG, Plowe CV, Doumbo OK.

PLoS One. 2013 Nov 18;8(11):e79323. doi: 10.1371/journal.pone.0079323. eCollection 2013.

Supplemental Content

Loading ...
Support Center